Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • byou678
    Member
    • Aug 2011
    • 52

    GO-slim Problem When Run Blast2GO, Help.

    Hi All,

    I load 10 example sequences into Blast2GO by choosing "Load 10
    Example Sequences" in the "File" menu. I run blast, mapping, annotation step by step, after doing the annotation augmentation by "Run ANNEX", I try to do " GO-Slim", it shows:
    10:24 Prepare data for GoSlim.
    10:24 6 Sequences send to preform GoSlim: goslim_generic.obo Error while generating GoSlim results: Error: SOAP message MUST NOT contain a Document Type Declaration(DTD); nested exception is:
    org.apache.axiom.om.OMException: SOAP message MUST NOT contain a Document Type Declaration(DTD)


    In addition, I download the example file ( b2g_example_file.zip) from Blast2GO Home Site, and use that data to run, the same problem occur:

    16:52 Prepare data for GoSlim.
    16:52 928 Sequences send to preform GoSlim: goslim_generic.obo Error while generating GoSlim results: Error: SOAP message MUST NOT contain a Document Type Declaration(DTD); nested exception is:
    org.apache.axiom.om.OMException: SOAP message MUST NOT contain a Document Type Declaration(DTD)


    Does anyone have the similar problem before?

    One more problem: When I right click one sequence to run " Draw Graph of Annotation", The graph should appear under "Go Graphs" of the Result Tabs. But it doesn't happen, only show me a " Graph-Sequence Distribution" Table under " Statistics" of the Result Tabs.

    ANY Ideas and Helps will be greatly appreciated. Look forward to the responses. Thanks All.
    Last edited by byou678; 09-11-2011, 07:40 AM.

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
18 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
18 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
25 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
38 views
0 reactions
Last Post SEQadmin2  
Working...